Ads
related to: simvastatin dangers in dogs treatment reviews consumer reportsnexlizet.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
The urgent warning comes after a recent review made by the government organization. ... the medication caused these effects. The news outlet reports the medication works using monoclonal ...
Simvastatin also reduced the numbers of other events like heart attacks, strokes, and revascularizations and MI significantly. [11] The Heart Protection Study evaluated the effects of simvastatin in people with risk factors including existing cardiovascular disease, diabetes, or stroke, but having relatively low LDL cholesterol. In this trial ...
Simvastatin: No tumorigenic effect was seen in a 72-week carcinogenicity study using mice at the low dose levels. However, at the higher dose levels (eight and 16 times the human dose equivalent), liver carcinomas and adenomas, lung adenomas, and adenomas of the Harderian gland occurred.
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
While there have been concerns about side-effects associated with statins (myopathy and rhabdomyolysis), these were rare in this study. [citation needed] The number needed to treat in the study was 57 to postpone one death and 19 to prevent one cardiovascular "event" (in those taking the drug simvastatin for 5 years). There was no mortality ...
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.